Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

86.66 +3.90 (+4.71%)

Streaming Delayed Price Updated: 3:37 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Volume	496,752
Open	82.32
Bid (Size)	86.63 (400)
Ask (Size)	86.82 (300)
Prev. Close	82.76
Today's Range	77.00 - 86.84
52wk Range	33.70 - 96.54
Shares Outstanding	62,107,572
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗

February 16, 2026

This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.

Via The Motley Fool

Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗

February 01, 2026

The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple.

Via The Motley Fool

Performance

YTD	-0.6%	-0.6%
1 Month	+4.3%	+4.3%
3 Month	-1.2%	-1.2%
6 Month	+52.4%	+52.4%
1 Year	+140.7%	+140.7%

More News

"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape

January 15, 2026

Via MarketMinute

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗

October 14, 2025

Via Stocktwits

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

January 07, 2026

Via ACCESS Newswire

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 05, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Protagonist (PTGX) Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

November 27, 2025

Via ACCESS Newswire

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 06, 2025

Via ACCESS Newswire

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

November 03, 2025

Via ACCESS Newswire

What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

October 28, 2025

Via Benzinga

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

October 27, 2025

Via ACCESS Newswire

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗

October 23, 2025

Via The Motley Fool

Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗

October 23, 2025

Via The Motley Fool

Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗

October 21, 2025

Via The Motley Fool

Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?

October 20, 2025

Via AB Newswire

2 Top Dividend Kings Every Income Investor Should Own ↗

October 20, 2025

Via The Motley Fool

Johnson & Johnson's M&A Strategy Is the Real Story for Investors ↗

October 18, 2025

Via MarketBeat

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗

October 14, 2025

Via Benzinga

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗

October 14, 2025

Via Stocktwits

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗

October 13, 2025

Via Benzinga

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗

October 13, 2025

Via Benzinga

Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears ↗

October 13, 2025

Via Chartmill

Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today ↗

October 10, 2025

Via The Motley Fool

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

October 10, 2025

Via Chartmill

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?

Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?

Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?

The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market

What is the current price of Protagonist Therapeutics, Inc. - Common Stock?

The current price of Protagonist Therapeutics, Inc. - Common Stock is 86.66

When was Protagonist Therapeutics, Inc. - Common Stock last traded?

The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 02/23/26 03:37 PM ET

What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?

The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 5.38B

How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?

Protagonist Therapeutics, Inc. - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.